

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Erodible Coatings Based on HPMC and Cellulase for Oral Time-Controlled Release of Drugs

Anastasia Foppoli, Alessandra Maroni*, Luca Palugan, Lucia Zema, Saliha Moutaharrik, Alice Melocchi,
Matteo Cerea, Andrea Gazzaniga

Università degli Studi di Milano
Dipartimento di Scienze Farmaceutiche
Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli"
via G. Colombo 71
20133 Milano, Italy

Corresponding author

*Alessandra Maroni

Università degli Studi di Milano
Dipartimento di Scienze Farmaceutiche
Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli"
via G. Colombo 71
20133 Milano, Italy
Tel +39 02 50324654
email: alessandra.maroni@unimi.it

27 **KEYWORDS**

28 Swellable/erodible delivery systems, pulsatile release, hydroxypropyl methylcellulose, press-coating,
29 cellulase, enzymatic degradation.

30

31 **ABSTRACT**

32 Oral drug delivery systems for time-controlled release, intended for chronotherapy or colon
33 targeting, are often in the form of coated dosage forms provided with swellable/soluble hydrophilic
34 polymer coatings. The latter are responsible for programmable lag phases prior to release, due to
35 their progressive hydration in the biological fluids. When based on high-viscosity polymers and/or
36 manufactured by press-coating, the performance of functional hydroxypropyl methylcellulose
37 (HPMC) layers was not fully satisfactory. Particularly, it encompassed an initial phase of slow
38 release because of outward diffusion of the drug through a persistent gel barrier surrounding the
39 core. To promote erosion of such a barrier, the use of a cellulolytic product (Sternzym[®] C13030)
40 was here explored. For this purpose, the dry mass loss behavior of tableted matrices based on
41 various HPMC grades, containing increasing percentages of Sternzym[®] C13030, was preliminarily
42 \studied, highlighting a clear and concentration-dependent effect of the enzyme especially with
43 high-viscosity polymers. Subsequently, Sternzym[®] C13030-containing systems, wherein the
44 cellulolytic product was either incorporated into a high-viscosity HPMC coating or formed a
45 separate underlying layer, were manufactured. Evaluated for release, such systems gave rise to more
46 reproducible profiles, with shortened lag phases and reduced diffusional release, as compared to the
47 reference formulation devoid of enzyme.

48

49

50

51 1. INTRODUCTION

52 Several drug delivery systems for time-controlled release into the gastrointestinal tract,
53 generally based on coated dosage forms or functional capsule shells, were proposed over the past
54 three decades for chronopharmaceutical and colon targeting applications (Gazzaniga et al., 2011;
55 Maroni et al., 2013, 2016; Melocchi et al., 2018). The relevant release-controlling layers were
56 obtained using polymers having different physico-chemical properties, including swellable/soluble
57 hydrophilic cellulose derivatives. By progressively interacting with the aqueous fluids, the latter
58 polymers defer the onset of drug release until extensive dissolution/erosion of the gel barrier they
59 form when undergoing glass-rubber transition.

60 The application of the erodible functional layer of delivery systems for time-controlled release
61 posed a novel challenge in the manufacturing of solid pharmaceuticals. The available techniques,
62 *i.e.* double-compression (press-coating) and spray-coating, were both attempted. Press-coating
63 offered advantages related to its solvent-free nature and, therefore, to the circumvented need for
64 time- and energy-consuming drying steps (Foppoli et al., 2017). For these reasons, it also
65 represented a technique with limited impact on the overall stability of the products. On the other
66 hand, it required considerable amounts of powdered material to be applied, thus restraining the
67 flexibility of the delivery technology. Moreover, depending on the physico-chemical and physico-
68 technological characteristics of the layer applied, it was demonstrated to yield excessively long-
69 lasting lag phases prior to release, which would be inconsistent with both the chronotherapeutic and
70 colon delivery goals pursued. Importantly, relatively thick coatings having porous structure, as
71 resulting from compaction processes, were also shown to give rise to initially slowed release due to
72 outward diffusion of the drug through the hydrated polymer layer before its complete
73 dissolution/erosion (Foppoli et al., 2019). This phenomenon would clearly clash with the prompt
74 and quantitative release mode that would be desired at the end of the lag phase, being associated
75 with diverse sigmoidal patterns.


76 Spray-coating was subsequently employed making use of hydro-organic film-forming
77 systems. The resulting coated units showed satisfactory physico-technological characteristics and
78 release performance. However, the use of organic solvents would no longer be of choice. Aqueous
79 spray-coating, undertaken mainly in view of greater regulatory acceptability, involved longer
80 processing time along with feasibility issues given the rheological characteristics of the film-
81 forming solutions. Despite all technical hurdles, aqueous-coated systems having the desired aspect
82 and mechanical resistance were obtained following proper setup of the operating conditions. While
83 the desired release patterns were attained with low-viscosity HPMC grades, the high-viscosity ones
84 partly failed to meet expectations (Maroni et al., 2002). In this respect, Methocel® K4M was shown
85 to bring about a phase of diffusional release that was poorly evident *in vitro* though of major impact
86 *in vivo*, thus impairing the overall performance of the delivery system that turned out more alike to
87 a reservoir formulation for prolonged release (Figure 1). Furthermore, due to the marked release-
88 deferring ability of such polymers, possible difficulties were anticipated in fine modulation of the
89 lag time through modification of the coating level.

90 Therefore, release issues associated with coatings based on high-viscosity swellable/soluble
91 polymers and/or manufactured by double-compression technique are still to be addressed. In order
92 to overcome the aforementioned limitations, thereby broadening the scope of application of such a
93 technique and of such polymers, formulation changes, to be introduced into the original design of
94 the erodible systems, were needed.

95 Based on these premises, the incorporation of cellulase, either in admixture with the
96 functional coating polymer or separately loaded within a contiguous layer, was here explored with
97 the aim of promoting erosion of the gel formed upon polymer hydration, thus preventing an
98 enduring diffusional barrier from building up and affecting the rate of drug release over an extended
99 time frame. Cellulases are enzymes or multienzymatic complexes produced by different
100 microorganisms, which catalyze breakdown of cellulose and other structurally-related
101 polysaccharides into glucose and cello-oligo saccharides (FAO, 1997). Such enzymes are widely

102 used in processing of food of plant origin, and in pulp and paper industry (Bhat, 2000; Bhat and
103 Bhat, 1997; Jonas and Farah, 1998). They also have medical and biomedical applications, for the
104 treatment of gastric phytobezoars and degradation of bacterial biofilms, and could be used as food
105 supplements for fiber digestion and prebiotic purposes (Kramer and Pochapin, 2012) (Exercise.com.
106 *Cellulase*, 2020). Exploitation of enzymes having cellulolytic activity has recently been proposed to
107 turn pharmaceutical excipient microcrystalline cellulose into nanocellulose with improved tensile
108 properties (Satyamurthy and Vigneshwaran, 2013).

109 In the present work, the potential impact of a cellulolytic product of common use in the food
110 industry (Sternzym[®] C13030) on the dissolution/erosion behavior of various HPMC grades was
111 preliminarily studied by incorporating it into tableted polymer matrices, used as a model
112 compression-coating, and performing dry mass loss experiments. Moreover, Sternzym[®] C13030-
113 containing erodible systems for time-controlled release having diverse configuration were
114 manufactured, using different coating techniques, and subsequently evaluated for release behavior.



115
116 Figure 1: saliva concentration profiles of acetaminophen after intake of uncoated cores and units
117 coated with Methocel[®] E5LV, E50LV and K4M up to 20% weight gain [adapted from
118 Maroni et al., 2002].

119
120

121

122

123 2. MATERIALS AND METHODS

124 2.1 Materials

125 Acetaminophen for direct compression (AMP, C.F.M., Italy), cellulose acetate propionate (CAP
126 482-20, Eastman-Kodak, Tennessee), colloidal silica (Aerosil[®] 200, Evonik, Germany),
127 ethylcellulose (Ethocel[®], Dow Italia, Italy), hydroxypropyl methylcellulose 2910 USP (Methocel[®]
128 E50LV, M_n=20000, Dow Italia) and 2208 USP (Methocel[®] K100LV, M_n=26000; Methocel[®] K4M,
129 M_n=86000; Methocel[®] K15M, M_n=120000; Methocel[®] K100M, M_n=220000), magnesium stearate
130 (Carlo Erba Reagenti, Italy), maltodextrin (Glucidex[®] IT19W, Roquette, France), microcrystalline
131 cellulose (Vivapur[®]101, JRS Pharma, Germany), sodium starch glycolate (Explotab[®], JRS Pharma,
132 Germany), Sternzym[®] C13030 (SternEnzym, Germany, a kind gift from IMCD Italia, Italy; 2500
133 u/g enzymatic activity, expressed as hemicellulase according to DNS method at pH 6.0 as reported
134 in the product technical data sheet).

135

136

137 2.2 Methods

138 Manufacturing of matrices

139 Flat-faced cylindrical matrices (diameter 25 mm, nominal weight 1.0 g) were prepared by a rotary
140 press (AM 8S, Officine Ronchi, Italy) from HPMC (Methocel[®] E50LV, Methocel[®] K100LV,
141 Methocel[®] K4M, Methocel[®] K15M and Methocel[®] K100M), either as such or in admixture with
142 Sternzym[®] C13030 (1, 5 and 10%) or maltodextrin (10%), under approximately 2000 kg
143 compaction force so that the resulting tablet had crushing strength in the range 70-100 N (crush
144 tester TBH30 Erweka, Germany; n=10). The matrices were provided with an impermeable film,
145 covering their whole surface except for one base, that was obtained by dipping into a 15% w/v CAP
146 solution in acetone.

147

148

149 Mass loss experiments

150 Partially coated units exposing a surface of constant area (n=3) were placed in the vessels of a
151 paddle dissolution apparatus (Dissolution System 2000, Distek, New Jersey) containing 150 mL of
152 deionized water thermostated at $37\pm 1^\circ\text{C}$, so that the distance from the stirrer bottom and the matrix
153 surface exposed to the fluid was 1.5 cm. The paddle rotation speed was set at 100 rpm. At fixed
154 time points, 15 ml of fluid was withdrawn, replaced with fresh medium, and dried at 80°C to
155 constant weight. Mass loss was assessed as the amount of solids recovered after drying of each fluid
156 sample, and the relevant data were plotted against time to build cumulative curves. The rate of mass
157 loss was calculated as the slope of the regression lines in the 1.5-6 h time frame.

158

159 Manufacturing of tablet cores

160 Acetaminophen (80.0%), microcrystalline cellulose (14.5%), sodium starch glycolate (4.5%),
161 magnesium stearate (0.5%) and colloidal silica (0.5%) were mixed in a V-blender (Erweka,
162 Germany). The mixture was tableted by a rotary press equipped with concave punches (diameter 4
163 mm, curvature radius 4 mm). The tablets were checked for weight (analytical balance BP211D
164 Sartorius Mechatronics, Germany; n=20), height and diameter (digital micrometer Mitutoyo, Japan;
165 n=20), crushing strength, friability (friabilometer TA3R Erweka, Germany) and disintegration time
166 (three-position disintegration apparatus DT3 Sotax, Switzerland, n=6). The weight, height,
167 diameter, crushing strength, friability and disintegration time were 39.0 ± 0.5 mg, 3.092 ± 0.028 mm,
168 4.034 ± 0.003 mm, $70\pm 4\text{N}$, $< 1\%$ and < 5 min, respectively.

169

170 Coating of tablet cores

171 One-layer systems: Methocel[®] K4M, either as such or manually mixed with Sternzym[®] C13030 at 1
172 and 5%, was applied onto tablet cores by manual press-coating using 80 mg of coating powder. Half
173 of the powder was first introduced into the die (\varnothing 6 mm) of the tableting machine. The tablet core

174 was positioned centrally onto the pre-compressed powder bed. Then, the remainder of the coating
175 powder was fed into the die and compaction forces of approximately 500 kg were applied, using
176 concave punches with 6 mm curvature radius.

177 Two-layer systems: an inner layer of Sternzym[®] C13030 and an outer layer of Methocel[®] K4M
178 were applied by aqueous spray-coating in rotating pan (Ø 12 cm, GS, I) equipped with a two-way
179 nozzle (mod 970/7-1 S75, Ø 1.2 mm, Düsen-Schlick, Untersiemau, Germany) and press-coating,
180 respectively. Sternzym[®] C13030 amounted to 1% or 5% w/w of the applied amount of Methocel[®]
181 K4M. In the two cases, coating solutions differing in composition were used for application of
182 Sternzym[®] C13030 (Table I). Particularly, the addition of maltodextrin was aimed at having the
183 same amount of solid material applied onto the cores by spray-coating, also enabling easier in-
184 process monitoring of the substrate growth. The cores were coated up to nominal weight gain of
185 11%, under the following operating conditions: batch size 100 g; inlet air temperature 60 °C;
186 product temperature 38 °C; pan rotation speed 30 rpm; nebulization air pressure 0.2 bar; solution
187 spray rate 2.9 g/min . Methocel[®] K4M was then applied by press-coating, as described above.

188

189

190

191

192 Table I. Percentage composition of the coating solutions used for application of Sternzym[®]
193 C13030 at 1% (A) or 5% (B) w/w of Methocel[®] K4M

	A	B
Sternzym [®] C13030	2	10
Maltodextrin	8	-
PVP	1	1
Distilled water	89	89

194

195

196

197

198

199

200 Characterization of coated systems

201 Coated systems were characterized for weight, height, diameter (n=20), crushing strength (n=10)
202 and friability. Coating thickness was calculated as half of the mean difference between the height
203 and diameter of coated units and tablet cores, respectively. Photomicrographs of cross-sectioned
204 systems were acquired by scanning electron microscope (SEM). Samples were gold-sputtered using
205 a plasma evaporator under vacuum, and the photomicrographs were acquired at an accelerated
206 voltage of 10 kV at 20 and 80x magnifications (Leo 1430, Carl Zeiss, Switzerland).

207 For release studies, an adapted disintegration test method was used in order to avoid previously
208 observed sticking of the swollen units to the vessels of the dissolution apparatus (Zema et al., 2007).
209 Tests (n=3) were performed by Ph. Eur. 9.8 disintegration apparatus. Each unit was inserted into a
210 basket-rack assembly so that only one of the 6 available tubes was occupied. The basket-rack
211 assemblies moved in separate vessels at a constant 29 to 32 cycles/min frequency through a 55±2
212 mm distance, immersed in 800 ml of distilled water at 37±1 °C. Fluid samples were withdrawn
213 automatically at predetermined time points, and acetaminophen was quantified by

214 spectrophotometer at 248 nm (Lambda 25, Perkin Elmer, Italy). In the cumulative release profiles
215 obtained, the duration of the lag phase prior to release (lag time) was assessed as the last time point
216 before steep increase of the curve.

217

218

219

220

221 **3. RESULTS AND DISCUSSION**

222 3.1 Evaluation of mass loss from HPMC matrices containing cellulase

223 The impact of cellulolytic enzymes on the performance of drug delivery systems based on
224 hydrophilic cellulose derivatives has never been in-depth investigated, at least to the best of our
225 knowledge. In order to preliminarily verify whether the enzyme may play any role in formulations
226 for time-controlled release, the mass loss behavior of HPMC matrices was studied in the presence
227 of cellulase. A commercially available enzymatic product (Sternzym[®] C13030), used in fruit and
228 vegetable processing, was employed for this purpose. Sternzym[®] C13030 contains, in admixture
229 with maltodextrin as a bulking agent, enzyme proteins with cellulolytic and various other hydrolytic
230 activities, such as xylanase, glucanase and pectinase. Sternzym[®] C13030 appeared as a light brown
231 powder formed from particles having $d_{10}=45.52\ \mu\text{m}$, $d_{50}=99.88\ \mu\text{m}$ and $d_{90}=203.01\ \mu\text{m}$ size, as
232 measured according to (Foglio et al., 2016).

233 Different HPMC grades, covering a broad spectrum of applications in pharmaceutical
234 formulation, were selected for the study: Methocel[®] E50LV, Methocel[®] K100LV, Methocel[®] K4M,
235 Methocel[®] K15M and Methocel[®] K100M, having viscosity of 2% w/v aqueous solutions in the 50-
236 100000 cps range at 20°C. Cylindrical matrices based on each of these polymers, containing
237 concentrations of Sternzym[®] C13030 of 1, 5 and 10%, were obtained by compaction and afterwards
238 provided with an impermeable partial coating, so that a single surface of constant area could be

239 exposed to the medium. Partially coated matrices containing no cellulase, either composed of
240 HPMC as such or in admixture with 10% of maltodextrin in the place of Sternzym[®] C13030, were
241 also manufactured for comparison purposes. All matrices were tested in stirred thermostated water,
242 and aliquots of fluid, withdrawn at programmed time points, were dried to constant weight in order
243 to assess the amount of solids lost throughout the experiment. Particularly, the dry mass retrieved
244 would result from *i*) dissolution of undegraded polymer, *ii*) enzymatic degradation of the polymeric
245 chains and/or *iii*) mechanical erosion of swollen portions of the sample.

246 The profiles of mass loss from matrices based on HPMC grades of increasing viscosity, with
247 or without Sternzym[®] C13030, are reported in Figures 2-6. During the test, the free surface of the
248 matrices showed smooth and homogeneous aspect, devoid of rough areas or evident dips, upon
249 interaction with water. Moreover, no eroded fragments of the swollen polymer matrix were noticed
250 in the medium.

251 The process of mass loss in the time frame from 1.5 to 6 h was almost linear in all cases,
252 although a tendency to initially slow mass loss could be observed, which was less pronounced with
253 increasing enzyme percentages. Mass loss was found clearly affected by the enzyme, turning out to
254 be enhanced in a concentration-dependent mode. Such an effect was generally highlighted even
255 when the cellulolytic product was added at 1%, *i.e.* at the lowest percentage in the investigated
256 range. Sternzym[®] C13030 was shown to impact on the mass loss behavior of matrices to a different
257 extent depending on the HPMC grade. In particular, when the enzymatic product was added at 10%
258 w/w, the rate of the process was almost doubled in the case of Methocel[®] E50LV and Methocel[®]
259 K100LV, while an approximately ten-fold higher rate of mass loss was observed with Methocel[®]
260 K4M, Methocel[®] K15M and Methocel[®] K100M. The greater differences observed in the case of the
261 high-viscosity grades of HPMC could be ascribed to the inherently thicker and thus more persistent
262 gel they form upon hydration, which would make enzymatic degradation of the polymer be
263 reflected in a more evident tendency to dissolution and susceptibility to mechanical erosion.

264 For comparison, the rates of mass loss obtained in the time frame from 1.5 to 6 h are
265 comprehensively reported in Figure 7. From the histograms, the more marked stepwise increase in
266 mass loss rate as a function of the concentration of Sternzym[®] C13030 shown by Methocel[®] K4M,
267 Methocel[®] K15M and Methocel[®] K100M matrices is highlighted. In spite of the diverse molecular
268 mass and viscosity, no major differences were observed among these polymers, which would be in
269 line with comparable mass loss behavior of the relevant matrices devoid of enzyme under the
270 investigated hydrodynamic conditions.


271 Moreover, the low-viscosity polymers, namely Methocel[®] E50LV and Methocel[®] K100LV,
272 considerably differed from each other in terms of extent to which the relevant mass loss behavior
273 was influenced by the enzyme. Indeed, although the mass loss rate in the absence of Sternzym[®]
274 C13030 was comparable, a much greater value was reached in the case of Methocel[®] K100LV
275 when the enzymatic product was present at 10%. This gap might be due to the higher hydrophilicity
276 of Methocel[®] K100LV *vs* Methocel[®] E50LV, in view of the lower degree of methoxyl substitution
277 of series K polymers, and/or to its greater viscosity.

278 In order to verify whether highly water-soluble maltodextrin contained in Sternzym[®]
279 C13030 may have played any role in bringing about the observed increase in mass loss rate, high-
280 viscosity HPMC-based matrices containing this excipient at 10% in the place of the enzymatic
281 product were also evaluated (Figures 4-6). The influence of the sole maltodextrin turned out
282 negligible. Indeed, the profiles of the maltodextrin-loaded matrices were almost superimposed on
283 those relevant to the matrices based on HPMC as such. Therefore, it could be ruled out that simple
284 osmotic and/or channeling effects, due to the soluble diluent contained in the enzymatic product,
285 may be responsible for the enhanced rate of mass loss. Moreover, these results indicate that the
286 cellulolytic activity of Sternzym[®] C13030 would not be impaired by compaction, at least at the
287 forces employed for manufacturing of the matrices.

288

289

290



291


292 Figure 2: profiles of mass loss vs time from Methocel[®] E50LV matrices containing differing
293 amounts of cellulase (bars indicate SD).

294

295

296

297




298

299 Figure 3: profiles of mass loss vs time from Methocel[®] K100LV matrices containing differing
300 amounts of cellulase (bars indicate SD).

301

302




303

304 Figure 4: profiles of mass loss vs time from Methocel[®] K4M matrices containing differing amounts
 305 of cellulase (bars indicate SD).
 306

307

308

309




310

311 Figure 5: profiles of mass loss vs time from Methocel[®] K15M matrices containing differing
 312 amounts of cellulase (bars indicate SD).
 313

314

315



316

317


318 Figure 6: profiles of mass loss vs time from Methocel[®] K100M matrices containing differing
 319 amounts of cellulase (bars indicate SD).

320

321

322

323



324

325 Figure 7: mass loss rate per unit area of matrices based on different HPMC grades as a function of
 326 Sternzym[®] C13030 concentration in the 1.5-6 h time frame (bars indicate 95% confidence
 327 interval).

328

329

330







331 3.2 Evaluation of systems coated with high-viscosity HPMC and cellulase

332 Once a clear effect of cellulase on mass loss from the polymeric matrices was demonstrated,
333 especially evident with the higher viscosity HPMC grades, the outcome of incorporating Sternzym[®]
334 C13030 into coated formulations for time-controlled release was evaluated. Among the high-
335 viscosity polymers investigated, which all showed comparable mass loss behavior, Methocel[®] K4M
336 was selected for the study based on *in vivo* results previously obtained when it was applied as a
337 functional coating layer. Indeed, such a polymer was demonstrated to impair the release
338 performance of the coated dosage forms by generating an extended phase of slow release possibly
339 due to diffusion of the drug through a persistent gel layer.

340 In order to broadly explore the potential role of the enzyme, the cellulolytic product was
341 incorporated, in nominal amounts of 1% and 5% with respect to the HPMC mass, into either the
342 HPMC coating (one-layer configuration: 1LC-1St and 1LC-5St) or an underlying layer (two-layer
343 configuration, 2LC-1St and 2LC-5St) of the delivery system (Table II). Press-coating was employed
344 for application of Methocel[®] K4M, both as such and in admixture with Sternzym[®] C13030, onto
345 immediate-release tablet cores. This technique was used in view of its well-known benefits as a
346 simple dry-coating process coupled, however, with the critical impact of the rather elevated amount
347 of coating powder needed, which would worsen the issues related to the use of a high-viscosity
348 polymer. When the system was manufactured in its two-layer configuration, the application of
349 Sternzym[®] C13030 as an aqueous solution was carried out by spray-coating.
350 Coated units having uniform aspect and satisfactory physico-technological characteristics were
351 obtained, irrespective of the configuration of the system (Figure 8). The compression-coatings
352 exhibited even surface. While the inner Sternzym[®] C13030 film appeared continuous and uniform
353 in thickness, the tableted layer, as expected, showed a more porous structure and higher variability
354 in thickness.

355

356 Table II: outline of the systems under investigation and main physico-technological characteristics

		Code	Nominal Sternzym concentration (% w/w on HPMC)	Weight (mg)	Coating (1 or 2 layers) thickness (µm)	Sternzym layer thickness* (µm)
uncoated core		UC		39.0±0.5		
one-layer HPMC coated system		1L.Me	-	120.2±1.5	813±14	
one-layer HPMC/Sternzym [®] coated systems		1L.Me1St	1	120.1±0.9	813±17	
		1L.Me5St	5	118.8±1.2	811±10	
two-layer HPMC/Sternzym [®] coated systems		2L.Me1St	1	120.0±1.6	801±12	70±9
		2L.Me5St	5	122.4±1.2	805±14	75±11


*thickness measured before application of the HPMC layer by press-coating

357
358
359
360
361
362
363
364
365
366
367
368

369



370



371

372 Figure 8: picture of a core tablet, a coated system and one- and two-layer cross-sectioned systems
373 (top image, left to right; graded notches in mm); SEM photomicrographs of a two-layer
374 cross-sectioned system at 20x and 80x magnification (bottom images, left to right).

375


376

377


378

379 The release performance of the systems manufactured in the one- and two-layer configurations
380 was comparatively evaluated vs. the Methocel[®] 4KM-coated reference formulation (1LC.Me). In
381 the absence of Sternzym[®] C13030, an average lag time of 540 min, *i.e.* the time to breakup of the
382 system as indicated by steep increase in the release rate, was obtained (Figure 9). The profiles were
383 characterized by marked variability and diffusional release covering most of the overall lag phase,
384 up to approximately 20% of the drug content. This particular release pattern would be in agreement
385 with the aforementioned pharmacokinetic results (Maroni et al., 2002).

386 The release curves from one-layer systems having Sternzym[®] C13030 within the HPMC coating
387 (1LC.Me1St and 1LC.Me5St) were reproducible, and lag times turned out considerably reduced as
388 a function of the amount of enzyme incorporated (Figure 10). The phase of slow outward diffusion
389 of the drug through the swollen polymer layer appeared largely restrained both in terms of extent
390 and duration. However, an earlier onset of this diffusion phenomenon was noticed with respect to
391 the Methocel[®] K4M-coated units devoid of enzyme. Because the time to first detection of the drug
392 in the test medium would result from the time the solvent takes to reach the core (swelling front
393 movement) on the one hand, and the time the drug in solution takes to diffuse through the hydrated
394 HPMC layer on the other, the presence of cellulase could have brought about faster water
395 penetration due to polymer degradation and consequently decreased viscosity of the gel barrier.
396 These concomitant phenomena would have also promoted erosion of the hydrated layer, thus
397 leading to shorter diffusional path to be covered by the drug tracer. Such findings would be
398 consistent with previously presented data of mass loss from matrices.
399




400
401 Figure 9: acetaminophen release profiles from uncoated cores and one-layer Methocel[®] K4M-
402 coated systems.
403



404

405 Figure 10: acetaminophen release profiles from one-layer Methocel® K4M/Sternzym® C13030-
 406 coated systems with increasing percentages of the enzymatic product.

407



408

409 Figure 11: acetaminophen release profiles from two-layer Methocel® K4M/Sternzym® C13030-
 410 coated systems with increasing percentages of the enzymatic product.

411

412

413

414 In the profiles relevant to two-layer systems, having overlaid Sternzym[®] C13030 and
415 Methocel[®] K4M layers (2LC.Me1St and 2LC.Me5St), the presence of the enzyme resulted in
416 shortened lag phases, less evident diffusional release and reduced variability as compared with the
417 system coated with HPMC only (1LC.Me) (Figure 11). Thus, the aqueous spray-coating process
418 used to apply Sternzym[®] C13030 did not apparently hinder the effects of cellulase, at least to a
419 major extent.

420 The difference in lag time observed between the one-layer reference formulation (1LC.Me)
421 and the Sternzym[®] C13030-containing two-layer systems (2LC.MeSt1 and 2LC.MeSt5) could only
422 be ascribed to the phase of acetaminophen release, occurring by diffusion and unit breakup, rather
423 than to that of aqueous medium penetration. Indeed, because of composition, thickness and
424 manufacturing techniques of the HPMC coatings being equal, the time the solvent takes to reach the
425 inner enzyme layer in the two-layer systems would be expected to approximately correspond to that
426 it takes to reach the core in the one-layer reference formulation without enzyme.

427 The impact of cellulase as incorporated in a separate layer (2L.MeSt1 and 2L.MeSt5),
428 however, was lower with respect to when it was mixed with the swellable polymer (1L.MeSt1 and
429 1L.MeSt5), and the influence of the enzyme concentration was also less pronounced.

430

431

432 **4. CONCLUSIONS**

433 Unsolved issues inherent in the performance of swellable/erodible coatings for time-controlled release,
434 particularly manufactured by press-coating and/or from high-viscosity HPMC needed to be addressed. With
435 the aim of promoting faster and more consistent erosion of the diffusional barrier established upon polymer
436 swelling, the incorporation of cellulolytic enzymes into either the coating or an underlying layer was here
437 proposed. The viability of this approach was first assessed by studying the mass loss behavior of tableted
438 matrices including increasing percentages of a commercially-available cellulolytic product in admixture with
439 HPMC of viscosity grades spanning a wide range. Supported by the positive outcome of the preliminary

440 investigation, novel cellulase-containing systems were manufactured in the two differently devised
441 configurations and evaluated. The release performance they provided was greatly improved as compared to
442 the original formulation without enzymes. Indeed, previously observed issues of variable, excessively
443 deferred in time and initially diffusional release were effectively prevented. Based on these overall results,
444 the use of cellulase was shown to be a potentially advantageous strategy to obtain the desired pulsatile
445 release behavior from time-controlled delivery systems having high-viscosity HPMC coatings, particularly
446 when applied by press-coating. This would open up new perspectives in the application of such a technique,
447 allowing functional cellulosic coatings to be manufactured with no need for using organic or aqueous
448 solvents. Interestingly, the work performed not only would point out a potential role of cellulase as a release
449 modulator but also suggest coupling diverse release-controlling polysaccharide agents with related hydrolytic
450 enzymes might represent a novel approach in oral delivery and formulation, worthy of future investigation.

451

452

453

454

455 **REFERENCES**

- 456 Bhat, M.K., 2000. Cellulases and related enzymes in biotechnology. *Biotechnol. Adv.* 18, 355–383.
457 [https://doi.org/10.1016/S0734-9750\(00\)00041-0](https://doi.org/10.1016/S0734-9750(00)00041-0)
- 458 Bhat, M.K., Bhat, S., 1997. Cellulose degrading enzymes and their potential industrial applications.
459 *Biotechnol. Adv.* 15, 583–620. [https://doi.org/10.1016/S0734-9750\(97\)00006-2](https://doi.org/10.1016/S0734-9750(97)00006-2)
- 460 FAO, 1997. Production of fuel alcohol from cellulosic biomass, in: *Renewable Biological Systems*
461 *for Alternative Sustainable Energy Production (FAO Agricultural Services Bulletin - 128).*
- 462 Foglio, A., Rinaldi, M., Segale, L., Palugan, L., Cerea, M., Vecchio, C., Pattarino, F., 2016.
463 Nanonized itraconazole powders for extemporaneous oral suspensions : Role of formulation
464 components studied by a mixture design. *Eur. J. Pharm. Sci.* 83, 175–183.
465 <https://doi.org/10.1016/j.ejps.2015.12.030>
- 466 Foppoli, A., Maroni, A., Moutaharrik, S., Melocchi, A., Zema, L., Palugan, L., Cerea, M.,
467 Gazzaniga, A., 2019. In vitro and human pharmacoscintigraphic evaluation of an oral 5-ASA
468 delivery system for colonic release. *Int. J. Pharm.* 572, 118723.
- 469 Foppoli, A.A., Maroni, A., Cerea, M., Zema, L., Gazzaniga, A., 2017. Dry coating of solid dosage
470 forms: an overview of processes and applications. *Drug Dev. Ind. Pharm.*
471 <https://doi.org/10.1080/03639045.2017.1355923>
- 472 Gazzaniga, A., Cerea, M., Cozzi, A., Foppoli, A., Maroni, A., Zema, L., 2011. A novel injection-
473 molded capsular device for oral pulsatile delivery based on swellable/erodible polymers.
474 *AAPS PharmSciTech* 12, 295–303. DOI: 10.1208/s12249-011-9581-6
- 475 Jonas, R., Farah, L.F., 1998. Production and application of microbial cellulose. *Polym. Degrad.*
476 *Stab.* 59, 101–106. [https://doi.org/10.1016/S0141-3910\(97\)00197-3](https://doi.org/10.1016/S0141-3910(97)00197-3)
- 477 Kramer, S.J., Pochapin, M.B., 2012. Ingestion of Diet Coke and Cellulase. *Gastroenterol. Hepatol.*
478 8, 770–772.
- 479 Maroni, A., Cerea, M., Foppoli, A., Palugan, L., Gervasutti, C., Giordano, F., Gazzaniga, A., 2002.
480 Investigation on an Oral System for Delayed Release and Colon Targeting: Comparative
481 Evaluation of Various HPMC Viscosity Grades as Coating Agents. in: *Proceed. Int'l Symp.*
482 *Control. Rel. Bioact. Mater.* p. 522.
- 483 Maroni, A., Zema, L., Cerea, M., Foppoli, A., Palugan, L., Gazzaniga, A., 2016. Erodible drug
484 delivery systems for time-controlled release into the gastrointestinal tract. *J. Drug Deliv. Sci.*
485 *Technol.* 32, 229–235. <https://doi.org/10.1016/j.jddst.2015.10.001>
- 486 Maroni, A., Zema, L., Loreti, G., Palugan, L., Gazzaniga, A., 2013. Film coatings for oral pulsatile
487 release. *Int. J. Pharm.* 457, 362– 371. <http://dx.doi.org/10.1016/j.ijpharm.2013.03.010>

488 Melocchi, A., Parietti, F., Maccagnan, S., Ortenzi, M.A., Antenucci, S., Briatico-Vangosa, F.,
489 Maroni, A., Gazzaniga, A., Zema, L., 2018. Industrial Development of a 3D-Printed
490 Nutraceutical Delivery Platform in the Form of a Multicompartment HPC Capsule. *AAPS*
491 *PharmSciTech* 19, 3343–3354. <https://doi.org/10.1208/s12249-018-1029-9>
492 Satyamurthy, P., Vigneshwaran, N., 2013. A novel process for synthesis of spherical nanocellulose
493 by controlled hydrolysis of microcrystalline cellulose using anaerobic microbial consortium.
494 *Enzyme Microb. Technol.* 52, 20–25. <https://doi.org/10.1016/j.enzmictec.2012.09.002>
495 Zema, L., Maroni, A., Foppoli, A., Palugan, L., Sangalli, M.E., Gazzaniga, A., 2007. Different
496 HPMC viscosity grades as coating agents for an oral time and/or site-controlled delivery
497 system: An investigation into the mechanisms governing drug release. *J. Pharm. Sci.* 96, 1527–
498 1536. <https://doi.org/10.1002/jps.20802>
499
500

501 **Acknowledgment**

502 SEM analysis was carried out at NOLIMITS, an advanced imaging facility established by Università degli
503 Studi di Milano.

504

505 **Disclosure of interest**

506 The authors report no conflict of interest.

507